Maria Buhl Borgstrøm1, Marie Louise Grøndahl2, Tobias Wirenfeldt Klausen3, Anne Kjærgaard Danielsen4, Thordis Thomsen5, Anette Gabrielsen6, Anne Zedeler7, Betina Boel Povlsen8, Christina Hnida9, Gitte Juul Almind10, Jens Fedder11, John Kirk12, Johnny Hindkjær13, Josephine G Lemmen14, Karsten Petersen15, Katrine Haahr16, Morten Rønn Petersen17, Steen Laursen18, Thomas Høst Hansen19, Ulla Breth Knudsen20, Ursula Bentin-Ley21, Thomas Larsen22, Ulrik Schiøler Kesmodel23. 1. Department of Obstetrics and Gynecology, The Fertility Clinic, Copenhagen University Hospital Herlev, Herlev & Aalborg University, Copenhagen, Denmark. Electronic address: maria.borgstroem@regionh.dk. 2. Department of Obstetrics and Gynecology, The Fertility Clinic, Copenhagen University Hospital Herlev, Herlev, Denmark. 3. Department of Hematology, Copenhagen University Hospital Herlev, Herlev, Denmark. 4. Department of Gastroenterology, Copenhagen University Hospital Herlev, Herlev & University of Copenhagen, Copenhagen, Denmark. 5. Department of Anaesthesiology, Copenhagen University Hospital Herlev, Herlev & University of Copenhagen, Copenhagen, Denmark. 6. The Fertility Clinic, Horsens Regional Hospital, Horsens, Denmark. 7. Department of Obstetrics and Gynecology, The Fertility Clinic, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark. 8. The Fertility Clinic, Skive Regional Hospital, Skive, Denmark. 9. The Fertility Unit, Aalborg University Hospital, Aalborg, Denmark. 10. Copenhagen Fertility Center, Copenhagen, Denmark. 11. The Fertility Clinic, Odense University Hospital, Odense, Denmark. 12. Maigaard Fertility Clinic, Aarhus N., Denmark. 13. Aagaard Fertility Clinic, Aarhus N., Denmark. 14. Vitanova Fertility Center, Copenhagen, Denmark. 15. VivaNeo Ciconia Fertility Clinic, Højbjerg, Denmark. 16. Stork IVF Clinic, Copenhagen, Denmark. 17. Department of Obstetrics and Gynecology, The Fertility Clinic, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. 18. The Fertility Clinic IVF-syd, Fredericia, Denmark. 19. The Fertility Clinic, Zealand University Hospital Køge, Køge, Denmark. 20. The Fertility Clinic at Horsens Regional Hospital & Aarhus University, Horsens, Denmark. 21. The Danish Fertility Clinic, Frederiksberg C., Denmark. 22. Danish Medical Data Center, Vallensbæk, Denmark. 23. The Fertility Unit, Aalborg University Hospital & Aalborg University, Aalborg, Denmark.
Abstract
OBJECTIVE: To study if the age of women undergoing assisted reproductive technology treatment associates with stage, morphology, and implantation of the competent blastocyst. DESIGN: Multicenter historical cohort study based on exposure (age) and outcome data (blastocyst stage and morphology and initial human chorionic gonadotrophin [hCG] rise) from women undergoing single blastocyst transfer resulting in singleton pregnancy/birth. SETTING: Sixteen private and university-based facilities. PATIENT(S): In this study, 7,246 women who, between 2014 and 2018, underwent controlled ovarian stimulation (COS) or frozen-thawed embryo transfer (FET) with a single blastocyst transfer resulting in singleton pregnancy were identified. Linking data to the Danish Medical Birth Registry resulted in a total of 4,842 women with a live birth being included. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): The competent blastocyst development stage (1-6), inner cell mass (A, B, C), trophectoderm (A, B, C), and initial serum hCG value. RESULT(S): Adjusted analysis of age and stage in COS treatments showed that for every 1-year increase in age there was a 5% reduced probability of the competent blastocyst assessed as being in a high stage at transfer. Comparison between hCG values in women 18-24 years and 25-29 years in both COS and FET showed significantly lower levels in the youngest women. CONCLUSION(S): The initial hCG rise was influenced by the age of the woman, with an identical pattern for hCG values in COS and FET treatments. In COS, the competent blastocyst had a reduced stage with increasing women's age.
OBJECTIVE: To study if the age of women undergoing assisted reproductive technology treatment associates with stage, morphology, and implantation of the competent blastocyst. DESIGN: Multicenter historical cohort study based on exposure (age) and outcome data (blastocyst stage and morphology and initial human chorionic gonadotrophin [hCG] rise) from women undergoing single blastocyst transfer resulting in singleton pregnancy/birth. SETTING: Sixteen private and university-based facilities. PATIENT(S): In this study, 7,246 women who, between 2014 and 2018, underwent controlled ovarian stimulation (COS) or frozen-thawed embryo transfer (FET) with a single blastocyst transfer resulting in singleton pregnancy were identified. Linking data to the Danish Medical Birth Registry resulted in a total of 4,842 women with a live birth being included. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): The competent blastocyst development stage (1-6), inner cell mass (A, B, C), trophectoderm (A, B, C), and initial serum hCG value. RESULT(S): Adjusted analysis of age and stage in COS treatments showed that for every 1-year increase in age there was a 5% reduced probability of the competent blastocyst assessed as being in a high stage at transfer. Comparison between hCG values in women 18-24 years and 25-29 years in both COS and FET showed significantly lower levels in the youngest women. CONCLUSION(S): The initial hCG rise was influenced by the age of the woman, with an identical pattern for hCG values in COS and FET treatments. In COS, the competent blastocyst had a reduced stage with increasing women's age.
Authors: Maria Buhl Borgstrøm; Marie Louise Grøndahl; Tobias W Klausen; Anne K Danielsen; Thordis Thomsen; Ursula Bentin-Ley; Ulla B Knudsen; Steen Laursen; Morten R Petersen; Katrine Haahr; Karsten Petersen; Josephine G Lemmen; Johnny Hindkjær; John Kirk; Jens Fedder; Gitte J Almind; Christina Hnida; Bettina Troest; Betina B Povlsen; Anne Zedeler; Anette Gabrielsen; Thomas Larsen; Ulrik S Kesmodel Journal: PLoS One Date: 2022-07-28 Impact factor: 3.752